Holy Stone Healthcare Co (ROCO:4194) Beta: 0.0540 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4194 Holy Stone Healthcare Co Ltd ROCO:4194
41 GF Score
Price NT$6.99
GF Value NT$3.93
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Holy Stone Healthcare Co Beta?

Holy Stone Healthcare Co ROCO:4194 +4.33% 41 Beta is 0.0540 as of Jul. 21, 2026. GuruFocus rates ROCO:4194 with a GF Score™ of 41/100 and a GF Value™ of NT$3.93 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-21), Holy Stone Healthcare Co's Beta is 0.0540.


Holy Stone Healthcare Co  (ROCO:4194) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Holy Stone Healthcare Co Beta Related Terms


Holy Stone Healthcare Co Beta Historical Data

* Premium members only.

The historical data trend for Holy Stone Healthcare Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Holy Stone Healthcare Co Beta Chart

Holy Stone Healthcare Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 2.09 1.23 1.18 0.00

Holy Stone Healthcare Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 1.23 1.18 0.00 0.00

ROCO:4194 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Holy Stone Healthcare Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Holy Stone Healthcare Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Holy Stone Healthcare Co's Beta distribution charts can be found below:

* The bar in red indicates where Holy Stone Healthcare Co's Beta falls into.


ROCO:4194
41GF Score
Holy Stone Healthcare Co Ltd ROCO:4194
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Holy Stone Healthcare Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0540 mean?
Holy Stone Healthcare Co (ROCO:4194) has a Beta of 0.0540 as of Jul. 21, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Holy Stone Healthcare Co and its competitors.
Is Holy Stone Healthcare Co's Beta too high?
Holy Stone Healthcare Co's current Beta is 0.0540. Overall, Holy Stone Healthcare Co has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Holy Stone Healthcare Co's Beta compare to VRTX and REGN?
Holy Stone Healthcare Co's Beta of 0.0540 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Holy Stone Healthcare Co and its competitors. Holy Stone Healthcare Co's current Beta is 0.0540. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Holy Stone Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Holy Stone Healthcare Co (ROCO:4194) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$3.93, compared to a current price of NT$6.99 — trading 77.9% above its estimated fair value. The current Beta is 0.0540. Holy Stone Healthcare Co's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Holy Stone Healthcare Co (ROCO:4194), the current Beta is 0.0540 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Holy Stone Healthcare Co (ROCO:4194) Overvalued in 2026?

Based on GuruFocus' analysis, Holy Stone Healthcare Co stock appears to be overvalued. The current stock price of NT$6.99 is trading 77.9% above its estimated GF Value™ of NT$3.93. GuruFocus considers Holy Stone Healthcare Co to be Significantly Overvalued.

Key valuation signals for ROCO:4194:

  • Beta: 0.0540
  • GF Value™: NT$3.93 vs. price of NT$6.99 (77.9% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4194 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Holy Stone Healthcare Co Business Description

Address Number 88, Section 1, Neihu Road, 4th Floor, Neihu District, Taipei, TWN, 11493
Holy Stone Healthcare Co Ltd is a Taiwan based company focused on a biopolymer drug delivery platform. It is involved in the development of new drugs and medical devices, especially hyaluronic acid related therapeutic products. The products of the company include RenehaVis, SportVis, TRUD, and GAF.
41GF Score

Get the complete analysis for ROCO:4194

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$6.99
Price
NT$3.93
GF Value